RECURSION PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $26.87 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-25
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $2.52M, a 62.09% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $4.61M, a 34.74% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-06-30 was $7.91M, a 123.62% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-03-31 was $11.82M, a 2.15% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $26.87M, a 6.67% increase from fiscal 2024.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $25.19M, a 22.77% decline from fiscal 2023.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $32.62M, a 16.43% increase from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $28.02M, a 23.81% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $2.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $7.14M derived: sum of 2 quarters · filed 2026-02-25 | $15.05M derived: sum of 3 quarters · filed 2026-02-25 | $26.87M 10-K · filed 2026-02-25 |
| 2025-09-30 | $4.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $12.53M derived: sum of 2 quarters · filed 2025-11-05 | $24.35M 10-Q · filed 2025-11-05 | $31.01M derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | $7.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $19.74M 10-Q · filed 2025-08-05 | $26.39M derived: sum of 3 quarters · filed 2025-08-05 | $29.82M derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | $11.82M 10-Q · filed 2025-05-05 | $18.48M derived: sum of 2 quarters · filed 2025-05-05 | $21.90M derived: sum of 3 quarters · filed 2025-05-05 | $25.44M derived: sum of 4 quarters · filed 2025-05-05 |
| 2024-12-31 | $6.66M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $10.08M derived: sum of 2 quarters · filed 2025-02-28 | $13.62M derived: sum of 3 quarters · filed 2025-02-28 | $25.19M 10-K · filed 2025-02-28 |
| 2024-09-30 | $3.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $6.96M derived: sum of 2 quarters · filed 2024-11-06 | $18.54M 10-Q · filed 2024-11-06 | $25.27M derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | $3.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $15.11M 10-Q · filed 2024-08-08 | $21.85M derived: sum of 3 quarters · filed 2024-08-08 | $35.23M derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | $11.57M 10-Q · filed 2024-05-09 | $18.31M derived: sum of 2 quarters · filed 2024-05-09 | $31.69M derived: sum of 3 quarters · filed 2024-05-09 | $40.67M derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | $6.73M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $20.11M derived: sum of 2 quarters · filed 2024-02-29 | $29.09M derived: sum of 3 quarters · filed 2024-02-29 | $32.62M 10-K · filed 2024-02-29 |
| 2023-09-30 | $13.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $22.36M derived: sum of 2 quarters · filed 2023-11-09 | $25.89M 10-Q · filed 2023-11-09 | $32.00M derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | $8.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $12.51M 10-Q · filed 2023-08-08 | $18.62M derived: sum of 3 quarters · filed 2023-08-08 | $26.24M derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | $3.53M 10-Q · filed 2023-05-08 | $9.64M derived: sum of 2 quarters · filed 2023-05-08 | $17.26M derived: sum of 3 quarters · filed 2023-05-08 | $23.94M derived: sum of 4 quarters · filed 2023-05-08 |
| 2022-12-31 | $6.11M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $13.73M derived: sum of 2 quarters · filed 2023-02-27 | $20.42M derived: sum of 3 quarters · filed 2023-02-27 | $28.02M 10-K · filed 2023-02-27 |
| 2022-09-30 | $7.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $14.30M derived: sum of 2 quarters · filed 2022-11-08 | $21.90M 10-Q · filed 2022-11-08 | $44.30M derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | $6.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $14.28M 10-Q · filed 2022-08-09 | $36.68M derived: sum of 3 quarters · filed 2022-08-09 | $41.43M derived: sum of 4 quarters · filed 2022-08-09 |
| 2022-03-31 | $7.60M 10-Q · filed 2022-05-10 | $30.00M derived: sum of 2 quarters · filed 2022-05-10 | $34.75M derived: sum of 3 quarters · filed 2022-05-10 | $39.92M derived: sum of 4 quarters · filed 2022-05-10 |
| 2021-12-31 | $22.40M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $27.14M derived: sum of 2 quarters · filed 2022-03-23 | $32.32M derived: sum of 3 quarters · filed 2022-03-23 | $36.77M 10-K · filed 2022-03-23 |
| 2021-09-30 | $4.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $9.92M derived: sum of 2 quarters · filed 2021-11-10 | $14.38M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $5.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $9.63M 10-Q · filed 2021-08-13 | ||
| 2021-03-31 | $4.46M 10-Q · filed 2021-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |